Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Who’s Hired? Sandoz Names New Japanese Head

As Stada Brings In A Former Sandoz Executive In Portugal

Executive Summary

Sandoz has appointed a new leader for its Japanese business following the acquisition of Aspen’s local operations, while Stada has brought in a former Sandoz and Pfizer executive to lead its Ciclum Farma unit in Portugal. Meanwhile, Julphar has a new CEO.

You may also be interested in...



Who’s Hired? Nichi-Iko Looks To Sandoz For Fresh Leadership

Nichi-Iko has revealed its choice of new leadership, looking to Sandoz Japan for its next president and CEO. Meanwhile, Ethypharm and Krka have made fresh appointments in the UK and Centrient has named a new chief quality officer.

Stada Names New Global Development Head

Stada has named Yann Brun to become the group’s new head of global development, portfolio, regulatory and business development, replacing Robert Knerr. The move is the latest in a string of key appointments at Stada as the firm builds on a series of acquisitions and deals.

Aspen Explains Logic Behind €642m Mylan Thrombosis Deal

Aspen Pharmacare last week announced the sale of its thrombosis business in Europe to Mylan for €642m ($762m). CEO Stephen Saad faced investors to detail the rationale for the US firm and what the planned transaction means for Aspen, including its material debt pile.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB149785

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel